# Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

> **NCT05420636** · PHASE2 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Small-cell Lung Cancer
- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Iadademstat
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05420636
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-21
- **Primary completion:** 2025-07-23
- **Final completion:** 2025-07-23
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Closed to accrual due to low probability of successful outcomes
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05420636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05420636, "Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05420636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*